NOSIUM (NOSIUM ) Q1 2026 earnings summary

Executive summary

• Q1 2026 marked a transformative period with focus on the reverse acquisition of Medicortex Finland Oyj and portfolio streamlining, including the sale of Dr Sannas Sweden AB to strengthen liquidity and align with new strategic direction.

• Secured a SEK 4 million interest-free bridge loan to meet NGM's capital requirements for the planned acquisition.

• Medicortex's collaboration with the US DoD on TBI diagnostics was extended, validating the target's technology.

Financial highlights

• Group net sales decreased by 19% to SEK 1,094k (1,345k) year-over-year; parent company sales rose 1% to SEK 80k (79k).

• Group operating loss widened to SEK -902k (-864k); parent company operating loss at SEK -672k (-546k).

• Group net result attributable to shareholders improved to SEK -901k (-1,130k); parent company net result at SEK -666k (-712k).

• Group cash flow from operations improved to SEK -143k (-839k); parent company to SEK 33k (-518k).

• Group equity ratio increased to 80% (75%); parent company at 82% (86%).

Outlook and guidance

• The company is progressing toward transformation into a medtech-focused entity, pending NGM approval of the Medicortex acquisition.

• Portfolio streamlining and capital strengthening are expected to support the new strategic direction.